← All trials
NCT01422616
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2012
- Primary completion
- Dec 1, 2018
- Completion date
- Feb 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 4700
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- University of New South WalesLead sponsor
- Conselho Nacional de Desenvolvimento Científico e TecnológicoCollaborator
- National Health and Medical Research Council, AustraliaCollaborator
- The Stroke Association, United KingdomCollaborator
- TakedaCollaborator
- Government of KoreaCollaborator
- University of New South WalesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.